No registrations found.
ID
Source
Brief title
Health condition
Anticoagulants.
Vitamin K antagonists.
Vitamin K
Coumarines.
Vitamine K antagonisten.
Vitamine K
Sponsors and support
Intervention
Outcome measures
Primary outcome
1. The difference between vitamin K levels in blood 4 hours after taking vitamin K tablets in comparison with vitamin K solution;
2. The difference in the number of INR-values lower than 2.0 when comparing vitamin K tablets with vitamin K solution in oil after 24 and 48 hours;
3. Difference in the decrease of INRs 24 hours after taking either vitamin K tablets or solution.
The difference in the number of INRs lower than 2.0 when comparing vitamin K tablets and solution after 24 and 48 hours.
Secondary outcome
1. The difference between area under the curve measured over 24 hours after taking vitamin K tablets in comparisson with vitamin K solution;
2. The difference in increase of the vitamin K levels in the blood 24 hours after taking either vitamin K tablets solution.
Background summary
Vitamin K solution was used for several years to antagonize the treatment with vitamin K antagonists. Vitamin K tablets came into the market as 'vitamin tablets' instead of medicines, but are easier to distribute and do have a longer shelf life. However, they are not shown to be as effective as the oral solution. We perform this study to investigate whether the bioavailability and effectiveness of the tablets and solution are comparable. Patients are therefore recruited from the anticoagulation clinic in Leiden, the Netherlands.
Study objective
The bioavailability and effectiveness of vitamin K tablets and solution are comparable.
Study design
Step 1: 0h;2h;4h;5h;6h;8h;10h; 24h
Step 2: 0h; 24h; 48h;
Step 3: 0h; 24h; 48h.
Intervention
Administration of vitamin K tablets or solution.
Department of Hematology,
P.O. Box 9600
Felix J.M. Meer, van der
Albinusdreef 2
Leiden 2300 RC
The Netherlands
+31 (0)71 5263901
f.j.m.van_der_meer@lumc.nl
Department of Hematology,
P.O. Box 9600
Felix J.M. Meer, van der
Albinusdreef 2
Leiden 2300 RC
The Netherlands
+31 (0)71 5263901
f.j.m.van_der_meer@lumc.nl
Inclusion criteria
1. Healthy subjects;
2. Patients being treated with phenprocoumon undergoing an invasive diagnostic or therapeutic procedure for which reducing of the INR is necessary;
3. Patients being treated with phenprocoumon having an INR above 7.0 for which reducing with vitamin K is necessary;
4. Age 18 years or older;
5. Informed consent.
Exclusion criteria
1. Being treated for liver failure;
2. Pregancy, pregnancy wish or lactational period;
3. Hemodialysis or peritoneal dialysis;
4. Participation in the self management program;
5. Inability to take care of own medication and/or proven non-compliance with treatment protocols.
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL3353 |
| NTR-old | NTR3485 |
| Other | METC LUMC : P10.177 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |